• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项针对绝经后女性中重度潮热减少的经实证验证的应答者定义。

An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women.

机构信息

Global Clinical Statistics, Bayer Pharma AG, Berlin, Germany.

出版信息

Menopause. 2012 Jul;19(7):799-803. doi: 10.1097/gme.0b013e31823de8ba.

DOI:10.1097/gme.0b013e31823de8ba
PMID:22228322
Abstract

OBJECTIVE

The aim of this study was to derive an empirically validated definition of treatment responders for the reduction of moderate to severe hot flushes in postmenopausal women.

METHODS

This study used prospective blinded data analysis from a placebo-controlled study to investigate the efficacy of a treatment of moderate to severe hot flushes in postmenopausal women. Seven hundred ten postmenopausal women with at least 50 moderate to severe hot flushes per week participated in the study. The participants recorded the number of moderate to severe hot flushes each day in a diary. They also assessed their satisfaction with treatment on a Clinical Global Impression-improvement rating scale. Changes in the weekly number of moderate to severe hot flushes were compared with participants' self-assessments to derive an empirically validated minimal clinically important difference. This anchor-based value was compared with the conventional half-SD rule for minimal clinically important difference in participant-reported outcomes.

RESULTS

Anchor- and distribution-based minimal clinically important differences between "no change/worse" and "minimally improved" were an absolute reduction of 19.1 and 18.6 in the weekly number of moderate to severe hot flushes, respectively. In addition, the threshold between "minimally improved" compared with "much improved or better" was determined, based on the anchor method, as an absolute reduction of 40.3 in the weekly number of moderate to severe hot flushes.

CONCLUSIONS

A responder was defined as having at least an improvement of 19.1 hot flushes per week at week 4 and an improvement of 40.3 hot flushes per week at week 12.

摘要

目的

本研究旨在为绝经后女性中度至重度热潮红的缓解制定一个经过实证验证的治疗反应者定义。

方法

本研究使用安慰剂对照研究的前瞻性盲数据分析,调查了一种治疗绝经后女性中度至重度热潮红的疗效。710 名每周至少有 50 次中度至重度热潮红的绝经后妇女参加了这项研究。参与者在日记中记录每天中度至重度热潮红的次数。他们还使用临床总体印象改善评定量表评估对治疗的满意度。每周中度至重度热潮红的数量变化与参与者的自我评估进行比较,以得出经过实证验证的最小临床重要差异。该基于锚的价值与参与者报告的结果中最小临床重要差异的传统半标准差规则进行了比较。

结果

基于锚和分布的“无变化/恶化”和“轻度改善”之间的最小临床重要差异分别为每周中度至重度热潮红绝对减少 19.1 和 18.6。此外,基于锚定方法,“轻度改善”与“明显改善或更好”之间的阈值确定为每周中度至重度热潮红绝对减少 40.3。

结论

定义治疗反应者为在第 4 周至少有 19.1 次热潮红改善,在第 12 周至少有 40.3 次热潮红改善。

相似文献

1
An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women.一项针对绝经后女性中重度潮热减少的经实证验证的应答者定义。
Menopause. 2012 Jul;19(7):799-803. doi: 10.1097/gme.0b013e31823de8ba.
2
[Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].[评估雌二醇屈螺酮片治疗绝经后中国健康女性绝经症状的疗效和安全性:一项随机、多中心、双盲、安慰剂对照的临床研究]
Zhonghua Fu Chan Ke Za Zhi. 2011 May;46(5):345-9.
3
A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.一项针对绝经后妇女中等到重度血管舒缩症状的最低有效剂量屈螺酮与 17β-雌二醇的随机、双盲、安慰剂对照研究。
Menopause. 2014 Mar;21(3):227-35. doi: 10.1097/GME.0b013e31829c1431.
4
Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.用于缓解绝经后女性潮热的最低有效经皮17β-雌二醇剂量:一项随机对照试验。
Obstet Gynecol. 2007 Oct;110(4):771-9. doi: 10.1097/01.AOG.0000284450.51264.31.
5
A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.一项多中心、前瞻性、随机、双盲、安慰剂对照研究,旨在调查含1毫克戊酸雌二醇/2毫克地诺孕素的连续联合激素治疗制剂对绝经后妇女潮热的疗效。
Maturitas. 2007 Oct 20;58(2):201-7. doi: 10.1016/j.maturitas.2007.08.004. Epub 2007 Sep 21.
6
0.5 vs. 1.0 mg estradiol in combination with drospirenone for the treatment of hot flushes.0.5毫克与1.0毫克雌二醇联合屈螺酮治疗潮热的对比研究
Climacteric. 2015;18(4):512-7. doi: 10.3109/13697137.2015.1036855. Epub 2015 May 22.
7
Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.雌二醇 1 毫克和屈螺酮 2 毫克作为激素替代疗法用于中国绝经后妇女。
Climacteric. 2011 Aug;14(4):472-81. doi: 10.3109/13697137.2011.553971. Epub 2011 Apr 6.
8
Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.1毫克雌二醇与2毫克屈螺酮对绝经后韩国女性的疗效及耐受性:一项双盲、随机、安慰剂对照、多中心研究
Maturitas. 2007 Aug 20;57(4):361-9. doi: 10.1016/j.maturitas.2007.03.004. Epub 2007 Apr 27.
9
Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.绝经后妇女用巴泽多昔芬/结合雌激素治疗无热潮症状天数。
Climacteric. 2013 Apr;16(2):252-7. doi: 10.3109/13697137.2012.717996. Epub 2012 Oct 4.
10
Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.血管舒缩性热潮和正常血压绝经后妇女的 24 小时动态血压:绝经后激素治疗的安慰剂对照试验。
Ann Med. 2010 Jul;42(5):334-43. doi: 10.3109/07853891003796760.

引用本文的文献

1
Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes.对女性血管舒缩症状体验的质性探索,以支持患者报告结局的内容效度。
J Patient Rep Outcomes. 2025 Jul 1;9(1):79. doi: 10.1186/s41687-025-00914-0.
2
Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause.对经历绝经相关血管舒缩症状的女性进行高频数字判别测验(HFDD)、患者报告结果测量信息系统简版身体功能8b量表(PROMIS SD SF 8b)和更年期症状问卷(MENQOL)的心理测量学评估。
J Patient Rep Outcomes. 2025 May 7;9(1):50. doi: 10.1186/s41687-025-00875-4.
3
Interpretation of Change in Novel Digital Measures: A Statistical Review and Tutorial.
新型数字测量变化的解读:统计回顾与教程
Digit Biomark. 2025 Feb 3;9(1):52-66. doi: 10.1159/000543899. eCollection 2025 Jan-Dec.
4
Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.验证和应用阈值来定义血管舒缩症状频率的有意义变化:SKYLIGHT 1 和 2 数据的汇总分析。
Adv Ther. 2024 Jul;41(7):2845-2858. doi: 10.1007/s12325-024-02849-2. Epub 2024 May 22.
5
Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause.绝经相关血管舒缩症状女性患者 MENQOL 量表的心理测量学评估。
Adv Ther. 2024 Jun;41(6):2233-2252. doi: 10.1007/s12325-024-02787-z. Epub 2024 Feb 24.
6
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.TX-001HR 在 REPLENISH 试验中与中重度血管舒缩症状严重程度的临床意义相关。
Menopause. 2020 Nov;27(11):1236-1241. doi: 10.1097/GME.0000000000001602.
7
Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.评估雌孕激素口服胶囊(TX-001HR)治疗中重度血管舒缩症状的临床意义。
Menopause. 2019 May;26(5):513-519. doi: 10.1097/GME.0000000000001261.